| BSc (Hons), PhD UQ
Head of Program, ACRF Drug Discovery Program
Contact: Professor Philip Hogge
Tel: +61 2 9382 1829
Email: phogg 'at' ccia.unsw.edu.au
Professor Philip Hogg joined CCIA in 2003 to establish the Australian Cancer Research Foundation (ACRF) Drug Discovery Program.
Professor Hogg received his PhD in biochemistry from the University of Queensland in 1987 and worked as a post-doctoral fellow at the University of Michigan in the USA and Lund University in Sweden. He has been at the University of New South Wales since 1991.
Professor Hogg and his team have described a novel way in which proteins work. This discovery is a new paradigm in biology and has been recognised by the most prestigious awards offered to younger Australian biomedical researchers: the Commonwealth Health Minister's Award for Excellence in Health and Medical Research and the GlaxoSmithKline Australia Award for Research Excellence.
Application of Professor Hogg’s basic research has led to the development of a novel anti-cancer drug and a novel tumour imaging agent, both of which are currently being tested in clinical trials in cancer patients.
Key publications
1. Lay, A.J., Jiang, X.-M., Kisker, O., Flynn, E., Underwood, A., Condron, R. and Hogg, P.J. (2000) Phosphoglycerate kinase acts in tumor angiogenesis as a disulphide reductase. Nature 408, 869-73.
2. Xie, L., Chesterman, C.N. and Hogg, P.J. (2001) Control of von Willebrand factor multimer size by thrombospondin-1. Journal of Experimental Medicine 193, 1341-49.
3. Matthias, L.J., Yam, P.T.W., Jiang, X.-M., Vandegraaff, N., Li, P., Poumbourios, P., Donoghue, N., and Hogg, P.J. (2002) Disulphide exchange in domain 2 of CD4 is required for entry of the Human Immunodeficiency Virus Type 1. Nature Immunology 3, 727-32.
4. Don, A.S., Kisker, O., Dilda, P., Donoghue, N., Zhao, X., Decollogne, S., Creighton, B., Flynn, E., Folkman, J. and Hogg, P.J. (2003) A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3, 497-509.
5. Dilda, P. J., Don, A. S., Tanabe, K. M., Higgins, V. J., Allen, J. D., Dawes, I. W. and Hogg, P. J. (2005) Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J Natl Cancer Inst 97, 1539-47. |
